First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion

Benzer Materyaller

• Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
  Yazar:: Xuesong Chen, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-02-01)
• First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion
  Yazar:: Zhengguo LI, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-03-01)
• Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports
  Yazar:: Yuan Zhang, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-01-01)
• First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
  Yazar:: Tia Cheunkarndee, BA, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-06-01)
• EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study
  Yazar:: Sen Yang, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-05-01)